Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost, 0.00013% · 5 trials · 2 indications
As measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye and only the study eye was used in the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
| Arm | Type | Description |
|---|---|---|
| Travoprost 0.003% | EXPERIMENTAL | Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months |
| TRAVATAN | ACTIVE_COMPARATOR | Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months |
| Travatan, Investigational | EXPERIMENTAL | - |
| Trav 0.00013% | EXPERIMENTAL | Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days |
| Trav 0.00033% | EXPERIMENTAL | Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days |
| Trav 0.001% | EXPERIMENTAL | Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days |
| Trav 0.00267% | EXPERIMENTAL | Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days |
| Vehicle | PLACEBO_COMPARATOR | Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days |
| Travoprost 0.0008% | EXPERIMENTAL | Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks |
| Travoprost 0.001% | EXPERIMENTAL | Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks |
| Travoprost 0.0012% | EXPERIMENTAL | Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks |
| TRAVATAN + Vehicle | ACTIVE_COMPARATOR | TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks |
| Name | Type | Description |
|---|---|---|
| Travoprost ophthalmic solution, 0.003% | DRUG | - |
| Travoprost ophthalmic solution, 0.004% | DRUG | - |
| Travoprost, Investigational | DRUG | One drop in study eye once daily for 13 days |
| Travoprost (TRAVATAN) | DRUG | One drop in study eye once daily for 13 days |
| Travoprost Ophthalmic Solution, 0.00013% | DRUG | Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose |
| Travoprost Ophthalmic Solution, 0.00033% | DRUG | Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose |
| Travoprost Ophthalmic Solution, 0.001% | DRUG | Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose |
| Travoprost Ophthalmic Solution, 0.00267% | DRUG | Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose |
| Travoprost Vehicle | DRUG | Inactive ingredients used as an active comparator |
| Travoprost ophthalmic solution, 0.0008% | DRUG | - |
| Travoprost ophthalmic solution, 0.0012% | DRUG | - |
| TRAVATAN | DRUG | - |
| Vehicle | OTHER | - |
| Travoprost/brinzolamide | DRUG | - |
Inclusion Criteria: * Diagnosis of open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension. * Qualifying intraocular pressure at both eligibility visits. * Understand and sign an informed consent form. * Other protocol-defined inclusio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Travoprost is used for lowering intraocular pressure in patients with ocular hypertension and glaucoma, including open-angle glaucoma and angle-closure glaucoma. It is a small molecule developed by Alcon Inc. for the ophthalmology therapeutic area and is currently in Phase 3 clinical development.
Travoprost is a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. It is being studied for its efficacy in treating open-angle glaucoma and ocular hypertension, with clinical trials comparing it to other prostaglandin analogs.
Travoprost is developed by Alcon Inc., a company traded under the ticker symbol ALC. Alcon is conducting clinical trials to evaluate the safety and efficacy of Travoprost in patients with glaucoma and ocular hypertension.
Travoprost is in Phase 3 clinical development. It has completed five clinical trials, including Phase 3 studies, with a total enrollment of 1,549 participants. The drug is investigational and not yet approved by regulatory authorities.
Travoprost has been studied in several clinical trials, including NCT00051142 and NCT00051155, which are Phase 3 trials comparing Travoprost to other glaucoma medications. Additional Phase 2 trials, such as NCT00637130 and NCT01298687, have also been completed to evaluate its safety and efficacy.
Travoprost is also known by the brand name Travatan. Clinical trials, such as NCT01298687, refer to the drug as TRAVATAN, confirming that Travoprost and Travatan are the same medication.